Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye

NCT ID: NCT02951975

Last Updated: 2019-08-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

246 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-25

Study Completion Date

2018-12-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study will evaluate the safety, efficacy, characteristics of patients, characteristics of physicians and quality of life in patients who are prescribed OZURDEX® as treatment for non-infectious uveitis of the posterior segment of the eye in France.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-infectious Uveitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OZURDEX®

Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of non-infectious uveitis affecting the posterior segment of the eye.

dexamethasone intravitreal implant

Intervention Type DRUG

Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dexamethasone intravitreal implant

Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

OZURDEX®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

-Patient with non-infectious uveitis affecting the posterior segment of the eye.

Exclusion Criteria

-Patient not residing in metropolitan France.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Allergan

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nathalie Mesnard

Role: STUDY_DIRECTOR

Allergan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Amiens

Amiens, , France

Site Status

IOP Institut Ophtalmologique de Picardie

Amiens, , France

Site Status

Centre Rétine Gallien

Bordeaux, , France

Site Status

Hopital Pellegrin

Bordeaux, , France

Site Status

CHI de Créteil

Créteil, , France

Site Status

CHU Dijon

Dijon, , France

Site Status

Centre Pôle Vision Val d'Ouest

Écully, , France

Site Status

Hopital Claude Huriez

Lille, , France

Site Status

Hopital De La Croix Rousse

Lyon, , France

Site Status

Clinique Monticelli

Marseille, , France

Site Status

Hopital de la Timone

Marseille, , France

Site Status

Hopital Gui De Chauliac

Montpellier, , France

Site Status

SEL Ophtalliance

Nantes, , France

Site Status

Hopital Hotel Dieu Et Hme

Nantes, , France

Site Status

CHU Pasteur 2

Nice, , France

Site Status

Hôpital Lariboisière (AP-HP)

Paris, , France

Site Status

GH Pitie Salpêtrière (AP-HP)

Paris, , France

Site Status

GH Cochin St Vincent De Paul (AP-HP)

Paris, , France

Site Status

Fondation Rothschild

Paris, , France

Site Status

Hopital La Milétrie

Poitiers, , France

Site Status

Chu Toulouse

Toulouse, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Bodaghi B, Brezin AP, Weber M, Delcourt C, Kodjikian L, Provost A, Velard ME, Barnier-Ripet D, Pinchinat S, Dupont-Benjamin L. Real-Life Efficacy, Safety, and Use of Dexamethasone Intravitreal Implant in Posterior Segment Inflammation Due to Non-infectious Uveitis (LOUVRE 2 Study). Ophthalmol Ther. 2022 Oct;11(5):1775-1792. doi: 10.1007/s40123-022-00525-8. Epub 2022 Jul 8.

Reference Type DERIVED
PMID: 35802252 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GMA-EAME-EYE-0368

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ozurdex for Macular Edema Post Membrane Peeling
NCT01273727 COMPLETED PHASE2/PHASE3
Study of FTY720 in Patients With Uveitis
NCT01791192 WITHDRAWN PHASE2
PREFERENTIAL Study
NCT04563559 WITHDRAWN PHASE2/PHASE3